Literature DB >> 30094031

Pathogenicity locus determinants and toxinotyping of Clostridioides difficile isolates recovered from Iranian patients.

A Aliramezani1, M Talebi2, A Baghani1, M Hajabdolbaghi3, M Salehi3, A Abdollahi4, S Afhami5, M Marjani6, F Golbabaei7, M A Boroumand8, A Sarrafnejad9, M Yaseri10, S Ghourchian1, M Douraghi1,11.   

Abstract

Little is known about the toxin profiles, toxinotypes and variations of toxin Clostridioides difficile C (tcdC) in Iranian C. difficile isolates. A total of 818 stool specimens were obtained from outpatients (n = 45) and hospitalized patients (n = 773) in Tehran, Iran, from 2011 to 2017. The 44 C. difficile isolates were subjected to PCR of toxin C. difficile A (tcdA), toxin C. difficile B (tcdB), tcdA 3'-end deletion, toxinotyping and sequencing of the tcdC gene. Thirty-eight isolates (86.36%) were identified as tcdA and tcdB positive, and the remaining six isolates (13.63%) were nontoxigenic. All tcdA- and tcdB-positive isolates yielded an amplicon of 2535 bp by PCR for the tcdA 3' end. Fourteen (36.84%), seventeen (44.73%) and seven (18.43%) isolates belonged to wild-type, toxin C. difficile C subclone3 (tcdC-sc3) and tcdC-A genotype of tcdC, respectively. Thirty-one isolates (81.57%) belonged to toxinotype 0, and seven isolates (18.42%) were classified as toxinotype V. This study provides evidence for the circulation of historical and hypervirulent isolates in the healthcare and community settings. Furthermore, it was also demonstrated that the tcdC-A genotype and toxinotype V are not uncommon among Iranian C. difficile isolates.

Entities:  

Keywords:  Clostridioides difficile; tcdA; tcdB; tcdC; toxinotyping

Year:  2018        PMID: 30094031      PMCID: PMC6072886          DOI: 10.1016/j.nmni.2018.07.003

Source DB:  PubMed          Journal:  New Microbes New Infect        ISSN: 2052-2975


Introduction

Historically known as a primary aetiologic agent of nosocomial antibiotic-associated diarrhoea, Clostridioides difficile has recently emerged in community settings [1], [2], [3]. C. difficile infections are toxin mediated and are manifested clinically as a spectrum of mild to life-threatening symptoms, from diarrhoea to pseudomembranous colitis [4]. An enterotoxin (toxin A, TcdA) and a cytotoxin (toxin B, TcdB) are the main virulence determinants of C. difficile [5]. The cytotoxic activity of TcdB can lead to diarrhoea, while progression of illness and initial damage of colon are attributed to the enteropathy effects of TcdA [6]. Although the majority of toxigenic strains harbour TcdA and TcdB (TcdA positive/TcdB positive), a proportion of strains carry only TcdB (TcdA negative/TcdB positive) [7]. The genes encoding TcdA and TcdB are located on the 19.6 kb pathogenicity locus (PaLoc), which also contains three open reading frames including toxin C. difficile E (tcdE), toxin C. difficile R (tcdR) and tcdC. TcdC plays an important role as negative regulator of TcdA and TcdB production [8]. Various alterations have been found in the PaLoc genes of C. difficile strains throughout the world, and these variations have remarkable consequences on the structure and function of TcdA and TcdC proteins. A notable alteration is the deletion of 1.8 kb within the 3′ end of tcdA gene which gives rise to the formation of TcdA-negative/TcdB-positive C. difficile strains [9]. While such strains are potentially toxigenic, they could not be detected by cytotoxicity assays because truncated TcdA lacks the ligand-binding domain [7]. Changes in the C terminus of TcdA (A3 fragment) and the N terminus of TcdB (B1 fragment) toxins lead to the definition of 34 variants toxinotypes (I to XXXIV). The most important toxinotypes that were isolated from humans are toxinotype 0, III, IV, V and VIII. The nucleotide polymorphisms in tcdC gene including mutations and/or deletions in coding regions may lead to premature stop codons and consequently truncation of the functional TcdC protein. The mutated TcdC might be associated with increased production of TcdA and TcdB, and accordingly the virulence of C. difficile [10]. Little is known about the toxin profiles, toxinotyping, and variations of tcdC in of Iranian C. difficile strains. Therefore, we analysed the toxin profiles and variations in tcdA and tcdC genes of C. difficile strains recovered from patients with diarrhoea.

Materials and methods

Setting and isolates

This study was conducted at the anaerobic bacteriology laboratory affiliated with the School of Public Health, Tehran University of Medical Sciences, Tehran, Iran. A total of 818 stool specimens were obtained from outpatients (n = 45) and hospitalized patients (n = 773). These patients were suspected of having C. difficile–associated diarrhoea and were referred to the anaerobic bacteriology laboratory from 17 referral tertiary hospitals or clinics located in different geographical areas of Tehran, Iran, from 2011 to 2017 (Table 1). After alcohol shock, stools were cultivated on cycloserine cefoxitin fructose agar and were incubated anaerobically at 37°C for 48 hours. The suspected colonies were identified as C. difficile by colony morphology, specific horse odor, Gram staining and proline–aminopeptidase test [11].
Table 1

Genetic profiles and molecular characteristic of Clostridioides difficile isolates

No.StrainYear of isolationSourceacdu2/tpi/cdd3/gluDtcdA/tcdBLok1/Lok3tcdA 3′ size (bp)tcdCtcdC deletion (bp)tcdC stop codon at 184 bpCPEToxinotype
1PC0022014H+/+/+/++/+2535+39++V
2PC0042014H+/+/+/++/+3100b++0
3PC0062014H+/+/+/++/+2535++V
4PC0082014H−/+/+/++/+3100b+39++0
5PC0092014H+/+/+/++/+3100b+39++0
6PC0102014H+/+/+/++/+2535++V
7PC0202014H+/+/+/++/+2535++0
8PC0212014H+/+/+/++/+2535++0
9PC0242014H+/+/+/++/+3100b++0
10PC0282015H+/+/+/++/+2535++0
11PC0352015H+/+/+/++/+2535++0
12PC0362015H+/+/+/++/+2535++0
13PC0482015H+/+/+/+−/−+-
14PC0492015H+/+/+/++/+2535++0
15PC0542015H+/+/+/++/+2535++0
16PC0562015H+/+/+/++/+2535++0
17PC0622015H+/+/+/++/+2535+39++V
18PC0632015O+/+/+/++/+2535++0
19PC0662015H+/+/+/++/+2535++0
20PC0692016O−/+/+/++/+2535+39++V
21PC0712011H+/+/+/++/+2535++0
22PC0732012H+/+/+/+−/−+-
23PC0742011H+/+/+/++/+2535++0
24PC0752011H+/+/+/+−/−+-
25PC0802016H+/+/+/+−/−+-
26PC0872016H−/+/+/++/+2535++0
27PC0892016H−/+/+/++/+2535++0
28PC091b2016H+/+/+/+−/−+-
29PC092b2016H−/+/+/++/+2535++0
30PC0962016H−/+/+/++/+2535+39++V
31PC0982016H+/+/+/++/+2535++0
32PC1012016H+/+/+/++/+2535++0
33PC1022016H+/+/+/+−/−+-
34PC1032016H+/+/+/++/+2535++0
35PC1062016H+/+/+/++/+2535+39++V
36PC1072016H+/+/+/++/+2535++0
37PC1112016H+/+/+/−+/+2535++0
38PC1122016H+/+/+/++/+2535++0
39PC1132016H+/+/+/−+/+2535++0
40PC1142016H+/+/+/++/+2535++0
41PC1152016H+/+/+/++/+2535++0
42PC1162016H+/+/+/++/+2535++0
43PC1172016H+/+/+/++/+2535++0
44PC1182017H+/+/+/++/+2535++0

Hospitalized patients (H) or outpatients (O).

Amplicon was obtained using A3C and A4N primers [19].

PCR assays

Genomic DNA extraction of C. difficile isolates was done using Chelex 100 (Bio-Rad, Hercules, CA, USA) [12]. For molecular identification of C. difficile isolates, we used gene-specific primers targeting C. difficile housekeeping genes including triose phosphate isomerase (tpi), glutamate dehydrogenase (gluD), C. difficile upstream 2 (cdu2) and C. difficile downstream 3 (cdd3) genes [13], [14], [15]. C. difficile isolates were also screened for toxin A (tcdA) and toxin B (tcdB) genes [15], [16]. To confirm complete absence of PaLoc, all tcdA- and tcdB-negative strains were tested with PCR using Lok1-Lok3 primers [17]. In addition, tcdA 3′ end (tcdA3′) deletion analysis was performed using NK9 and NKV011 primers [18]. The entire tcdC gene of isolates was amplified using C1 and C2 primers [16], and subsequently the PCR products were subjected to sequencing.

Toxinotyping

All tcdA- and tcdB-positive isolates were subjected to toxinotyping using A3 and B1 primers that were previously described [19].

Toxigenic culture

The toxigenic culture of C. difficile isolates was performed as follows: three to five colonies of a pure culture of bacteria were subcultured on brain–heart infusion broth and incubated anaerobically for 3 to 5 days at 37°C. After centrifugation and filtration, brain–heart infusion supernatant containing toxin was added to a 96-well microplate containing 104 Vero cell line. After examination of the cell line at 24 and 48 hours under 5% CO2 at 37°C incubation conditions, cytopathic effects were recorded if 50% or more of the Vero cells were rounded [20].

Nucleotide sequence accession number

The nucleotide sequences of tcdC gene variants including wild type, truncated variant tcdC-A allele and tcdC-sc3 allele were deposited in GenBank under the accession numbers, indicated in Table 2.
Table 2

tcdC genotypes of Clostridioides difficile isolates

No.StrainMutation (nucleic acid residues)tcdC genotypeGenBank accession no.
1PC002G → T (53)/A → T (117)/C → T (120)/C → T (183)/C → T (184) (stop codon)/A → G (330)/G → T (430)/A → C (516)/T → A (558) (stop codon)/T → A (585)/T → C (660)/39bp deletion (341–379)tcdC-AMG675257
2PC004G → T (148)tcdC-sc3MG675248
3PC006G → T (148)tcdC-sc3MG675249
4PC008Wild typeMG675253
5PC009G → T (53)/A → T (117)/C → T (120)/C → T (183)/C → T (184) (stop codon)/A → G (330)/G → T (430)/A → C (516)/T → A (558) (stop codon)/T → A (585)/T → C (660)/39bp deletion (341–379)tcdC-AMG675258
6PC010G → T (53)/A → T (117)/C → T (120)/C → T (183)/C → T (184) (stop codon)/A → G (330)/G → T (430)/A → C (516)/T → A (558) (stop codon)/T → A (585)/T → C (660)/39bp deletion (341–379)tcdC-AMG675259
7PC020G → T (148)tcdC-sc3MG569922
8PC021G → T (148)tcdC-sc3MG675250
9PC024Wild typeaMG596349
10PC028Wild typeMG596350
11PC035G → T (148)tcdC-sc3MG655373
12PC036G → T (148)tcdC-sc3MG655374
13PC049G → T (148)tcdC-sc3MG655375
14PC054G → T (148)tcdC-sc3MG675251
15PC056G → T (148)tcdC-sc3MG655376
16PC062G → T (53)/A → T (117)/C → T (120)/C → T (183)/C → T (184) (stop codon)/A → G (330)/G → T (430)/A → C (516)/T → A (558) (stop codon)/T → A (585)/T → C (660)/39bp deletion (341–379)tcdC-AMG581978
17PC063G → T (148)tcdC-sc3MG655377
18PC066G → T (148)tcdC-sc3MG675238
19PC069G → T (53)/A → T (117)/C → T (120)/C → T (183)/C → T (184) (stop codon)/A → G (330)/G → T (430)/A → C (516)/T → A (558) (stop codon)/T → A (585)/T → C (660)/39bp deletion (341–379)tcdC-AMG675239
20PC071G → T (148)tcdC-sc3MG675240
21PC074Wild typeMG675241
22PC087G → T (148)tcdC-sc3MG675242
23PC089Wild typeMG675243
24PC092bWild typeMG675244
25PC096G → T (53)/A → T (117)/C → T (120)/C → T (183)/C → T (184) (stop codon)/A → G (330)/G → T (430)/A → C (516)/T → A (558) (stop codon)/T → A (585)/T → C (660)/39bp deletion (341–379)tcdC-AMG675245
26PC098G → T (148)tcdC-sc3MG675246
27PC101G → T (148)tcdC-sc3MG675247
28PC103Wild typeMG675255
29PC106G → T (53)/A → T (117)/C → T (120)/C → T (183)/C → T (184) (stop codon)/A → G (330)/G → T (430)/A → C (516)/T → A (558) (stop codon)/T → A (585)/T → C (660)/39bp deletion (341–379)tcdC-AMG675260
30PC107Wild typeMG675256
31PC111Wild typeMG788278
32PC112Wild typeMG788279
33PC113Wild typeMG788280
34PC114G → T (148)tcdC-sc3MG788284
35PC115G → T (148)tcdC-sc3MG788285
36PC116Wild typeMG788281
37PC117Wild typeMG788282
38PC118Wild typeMG788283

CPE, cytopathic effects.

Published sequence of Clostridioides difficile strain VPI10463 was used as reference strain for comparison of all sequences [34].

Results

Of 818 stool samples from outpatients and hospitalized patients, 44 isolates (5.37%) were identified as C. difficile based on detection of tpi, gluD, cdu-2 or cdd-3 (Table 1). Mean and standard deviation of patient age was 53.89 ± 22.44 years. Of 44 isolates, 38 (86.36%) were tcdA and tcdB positive and the remaining 6 (13.63%) isolates were tcdA and tcdB negative and nontoxigenic. All tcdA- and tcdB-negative isolates were positive in PCR reaction using Lok1-Lok3 primers and had 769 bp amplicon (Table 1). Genetic profiles and molecular characteristic of Clostridioides difficile isolates Hospitalized patients (H) or outpatients (O). Amplicon was obtained using A3C and A4N primers [19]. Of the 38 tcdA- and tcdB-positive isolates, all isolates yielded an amplicon of 2535 bp by PCR amplification for the tcdA 3′ end, thus confirming no deletion at this region. Using NK9 and NKV011 primers, six isolates that were tcdA and tcdB negative also were negative in tcdA 3′-end analysis. Of 38 toxigenic isolates, 31 isolates (81.57%) belonged to toxinotype 0, and 7 (18.42%) were classified as toxinotype V (Table 1). Among the toxigenic isolates, 14 C. difficile isolates (36.84%) had no deletion in tcdC sequences and were assigned to the wild-type tcdC genotype. Seventeen isolates (44.73%) contained a G → T transition at nucleotide 148 and belonged to tcdC-sc3 genotype. Seven isolates (18.43%) had deletion of 39 bp and also a C → T transition at nucleotide 184, and represented the tcdC-A genotype. The latter transition is proposed to result in truncation of the TcdC protein (Table 2). tcdC genotypes of Clostridioides difficile isolates CPE, cytopathic effects. Published sequence of Clostridioides difficile strain VPI10463 was used as reference strain for comparison of all sequences [34].

Discussion

We found that 5% of patients harboured C. difficile as either toxigenic or nontoxigenic isolates. This proportion is concordant with the previous report from Tehran, Iran, using enzyme-linked immunosorbent assay [21]. Using PCR for detection of tcdA and tcdB, we demonstrated that the majority of C. difficile isolates harboured tcdA and tcdB genes (Table 1). On the other hand, the isolates with no amplicon for tcdA/tcdB were confirmed to be nontoxigenic by a positive assay yielding an amplicon of 769 bp using Lok1 and Lok3 (Table 1) [17]. The frequency of toxigenic isolates tested in the current study (86.36%) was slightly higher than another study (84.2%) reported from Tehran, Iran [22]. In neighbouring countries such as Kuwait, the rate of toxigenic C. difficile was reported to be 0.54% to 64.6% [23], [24]. This difference might be partly related to the sample size, the target population and mainly to the primer set used in the current study. We used the primers targeting the 5′ end of the tcdA gene [15] and amplifying the conserved region and nonrepeating fragment of tcdA. Using this set of primers, all but the nontoxigenic isolates yielded amplicons, and as expected, the negative result for PCR was unlikely unless the isolates had a large deletion in tcdA [15]. Therefore, the isolates harbouring the tcdA gene was subsequently assayed for tcdA deletion in the 3′ end. Analysis of the 3′ end of tcdA revealed that all the isolates except four (PC004, PC008, PC009, PC024) produced an amplicon of 2535 bp using primers NK9-NKV011 (Table 1) [18]. While no amplicon was observed for the latter four isolates in PCR of the 3′ end, the amplicons of 3100 bp were noted using the primers directed at the A3 fragment used for toxinotyping [19]. Altogether, the isolates with a 2535 bp amplicon or 3100 bp were considered ToxA+/ToxB+ (Table 1). Toxinotyping of tcdA- and tcdB-positive isolates showed that these isolates belonged to toxinotype 0 or V. The most predominant toxinotype in our study was toxinotype 0, and this toxinotype showed no changes in tcdA and tcdB gene sequences (Table 1) [19]. Previous studies indicated that the C. difficile isolates with the entire repeating region of tcdA had toxinotype 0 and V [25], [26]. Jalali et al. [27] also found that toxinotype 0 was the prevalent toxinotype in an Iranian hospital. The most frequent toxinotypes in Asia are toxinotype 0 and VIII [24], [28]. Two studies reported that 71.4% and 7.69% of C. difficile toxinotypes in different hospitals in Kuwait and Lebanon belonged to toxinotype 0, respectively [24], [29]. These data show the minor changes in PaLoc either in Iran or Asia. With respect to clinical manifestations, either the nontoxigenic or toxigenic isolates were recovered from symptomatic patients who had diarrhoea. One possible explanation for recovery of the nontoxigenic C. difficile isolates might be the presence of such isolates as a member of intestinal microbiota [30]. In other words, the clinical manifestations may not be associated with the colonization of intestine by C. difficile or its carriage by patients, and only the intake of antibiotics may contribute to the development of antibiotic-associated diarrhoea [31]. For instance, one of the nontoxigenic isolates was recovered from a 54-year-old woman with HIV and toxoplasmosis. This patient was hospitalized for a long period, was subjected to the antimicrobial therapies and finally died. The patient had several predisposing factors, but it is difficult to conclude whether the nontoxigenic isolate was significantly implicated in diarrhoea. Another explanation is that apart from toxins, other virulence factors of C. difficile, particularly the colonization factors, may induce a pathologic response in vulnerable patients [32] and consequently give rise to disease. It has been reported that up to 50% of C. difficile isolated from healthy volunteers and asymptomatic hospitalized patients were nontoxigenic strains. Although there are several case reports describing the possible role of nontoxigenic isolates as risk or protective factor [33], further studies are needed to assess the function of nontoxigenic isolates in inducing C. difficile–associated clinical outcomes. We identified three types of tcdC genes in our isolates using sequencing: wild type, tcdC-A and tcdC-sc3 genotypes. The tcdC-A genotype is characterized by the existence of nonsense mutation at nucleotide 184 and 39 bp deletion at nucleotides 341 to 379 [34]. Toxinotyping revealed that all the isolates that had 39 bp deletion in tcdC gene belonged to toxinotype V, except two isolates. The isolates with no changes in tcdC gene were classified as toxinotype 0 except two isolates that belonged to toxinotype V (Table 1, Table 2). Isolates with TcdC truncation and toxinotype V may cause severe infections in humans and animals and may be identified as hypervirulent strains [35]. Hypervirulent C. difficile strains also express binary toxins (cdtA and cdtB) that may increase the severity of disease [35]. Little is known about the heterogenicity of C. difficile toxin genes in Iranian isolates, especially in Tehran. Jalali et al. [27] found that 0, V and XXIV toxinotypes were predominant in Isfahan. In our study, the six isolates with tcdC-A genotype were also positive for binary toxin (cdtA, cdtB) except one isolate using gene-specific PCR (data not shown). These six cdtA- and cdtB-positive isolates also belonged to toxinotype V. Six isolates of tcdC-A genotype were obtained from hospitalized patients and one from an outpatient (Table 1, Table 2). Jalali et al. [27] also reported that the isolates that possess 39 bp deletion in tcdC gene belonged to toxinotype V isolated from hospitalized patients. Persson et al. [15] and Spigaglia et al. [16] reported that all the isolates that have a 39 bp deletion in tcdC gene may belong to toxinotypes V, VI and VII. Among the tcdC genotypes, the tcdC-sc3 genotype has the highest frequency, as reported in other studies (Table 2) [34,]. This study provides molecular evidence that the isolates with either toxigenic or nontoxigenic profiles are circulating in the healthcare and community settings. Furthermore, it was also demonstrated that the tcdC-A genotype and toxinotype V is not uncommon among Iranian C. difficile isolates. This finding sheds light on the possibility of the contribution of hypervirulent isolates in C. difficile infections in addition to historical isolates of C. difficile.
  35 in total

1.  Deletions in the repeating sequences of the toxin A gene of toxin A-negative, toxin B-positive Clostridium difficile strains.

Authors:  H Kato; N Kato; S Katow; T Maegawa; S Nakamura; D M Lyerly
Journal:  FEMS Microbiol Lett       Date:  1999-06-15       Impact factor: 2.742

Review 2.  Antibiotics and hospital-acquired Clostridium difficile-associated diarrhoea: a systematic review.

Authors:  Claudia Thomas; Mark Stevenson; Thomas V Riley
Journal:  J Antimicrob Chemother       Date:  2003-05-13       Impact factor: 5.790

3.  Clostridium difficile infection: a review of the literature.

Authors:  Fahmi Yousef Khan; Abdul-Naser Elzouki
Journal:  Asian Pac J Trop Med       Date:  2014-09       Impact factor: 1.226

4.  Editorial commentary: Changing epidemiology of Clostridium difficile and emergence of new virulent strains.

Authors:  Stuart Johnson
Journal:  Clin Infect Dis       Date:  2014-04-04       Impact factor: 9.079

Review 5.  Clostridium difficile infection: toxins and non-toxin virulence factors, and their contributions to disease establishment and host response.

Authors:  Gayatri Vedantam; Andrew Clark; Michele Chu; Rebecca McQuade; Michael Mallozzi; V K Viswanathan
Journal:  Gut Microbes       Date:  2012-03-01

6.  Lack of association of tcdC type and binary toxin status with disease severity and outcome in toxigenic Clostridium difficile.

Authors:  Simon D Goldenberg; Gary L French
Journal:  J Infect       Date:  2011-03-21       Impact factor: 6.072

7.  Molecular analysis of the pathogenicity locus and polymorphism in the putative negative regulator of toxin production (TcdC) among Clostridium difficile clinical isolates.

Authors:  Patrizia Spigaglia; Paola Mastrantonio
Journal:  J Clin Microbiol       Date:  2002-09       Impact factor: 5.948

8.  Prevalence of Clostridium difficile toxinotypes in infected patients at a tertiary care center in Lebanon.

Authors:  Romy Moukhaiber; George F Araj; Kohar Annie B Kissoyan; Katia A Cheaito; Ghassan M Matar
Journal:  J Infect Dev Ctries       Date:  2015-07-30       Impact factor: 0.968

9.  A novel toxinotyping scheme and correlation of toxinotypes with serogroups of Clostridium difficile isolates.

Authors:  M Rupnik; V Avesani; M Janc; C von Eichel-Streiber; M Delmée
Journal:  J Clin Microbiol       Date:  1998-08       Impact factor: 5.948

10.  Clinical importance and representation of toxigenic and non-toxigenic Clostridium difficile cultivated from stool samples of hospitalized patients.

Authors:  Stojanovic Predrag; Kocic Branislava; Stojanovic Miodrag; Miljkovic-Selimovic Biljana; Tasic Suzana; Miladinovic-Tasic Natasa; Babic Tatjana
Journal:  Braz J Microbiol       Date:  2012-06-01       Impact factor: 2.476

View more
  1 in total

1.  Isolation and characterization of a multidrug-resistant Clostridioides difficile toxinotype V from municipal wastewater treatment plant.

Authors:  Akram Baghani; Mahmood Alimohammadi; Amir Aliramezani; Maliheh Talebi; Alireza Mesdaghinia; Masoumeh Douraghi
Journal:  J Environ Health Sci Eng       Date:  2020-09-26
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.